Skip to content

Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer

Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036921
Enrollment
Unknown
Registered
2020-08-25
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic mass

Interventions

Sponsors

Department of Gastroenterology, Shanghai Changhai hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. age 18-75 years,male or female; 2. diagnosis or suspection of solid pancreatic mass based on previous imaging examination (ultrasonography, CT or MRI); 3. lesion diameter larger than 1 cm; 4. signed informed consent letter.

Exclusion criteria

Exclusion criteria: 1.Pregnant female; 2.Pancreatic cystic lesions; 3.Anticoagulant/antiplatelet therapy cannot be suspended; 4.unable or refuse to provide informed consent; 5.Coagulopathy (platelet count 1.5); 6.Severe cardiopulmonary dysfunction that cannot tolerate intravenous anesthesia; 7.with history of mental disease; 8.other medical conditions that are not suitable for EUS-FNA.

Design outcomes

Primary

MeasureTime frame
SEN, SPE, ACC, AUC of ROC;consistency;

Secondary

MeasureTime frame
Survival time;

Countries

China

Contacts

Public ContactKaixuan Wang

Shanghai Changhai hospital

wangkaixuan224007@sina.com+86 13585673477

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026